BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 33897597)

  • 1. Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy.
    Valencia-Sanchez C; Zekeridou A
    Front Neurol; 2021; 12():642800. PubMed ID: 33897597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurological complications of immune checkpoint inhibitor cancer immunotherapy.
    Zivelonghi C; Zekeridou A
    J Neurol Sci; 2021 May; 424():117424. PubMed ID: 33812689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
    Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
    Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.
    Vilaseca A; Farina A; Villagrán-García M; Pegat A; Benaiteau M; Ciano-Petersen NL; Do LD; Rogemond V; Gonçalves D; Psimaras D; Birzu C; Honnorat J; Joubert B
    J Neurol; 2024 Jun; 271(6):3279-3290. PubMed ID: 38467790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies.
    Sechi E; Zekeridou A
    J Thorac Oncol; 2021 Mar; 16(3):381-394. PubMed ID: 33188910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitor-associated central nervous system autoimmunity.
    Valencia-Sanchez C; Sechi E; Dubey D; Flanagan EP; McKeon A; Pittock SJ; Zekeridou A
    Eur J Neurol; 2023 Aug; 30(8):2418-2429. PubMed ID: 37151179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
    Fonseca E; Cabrera-Maqueda JM; Ruiz-García R; Naranjo L; Diaz-Pedroche C; Velasco R; Macias-Gómez A; Milisenda JC; Muñoz-Farjas E; Pascual-Goñi E; Gállego Perez-Larraya J; Saiz A; Dalmau J; Blanco Y; Graus F; Martinez-Hernandez E;
    Lancet Neurol; 2023 Dec; 22(12):1150-1159. PubMed ID: 37977714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes.
    Farina A; Villagrán-García M; Vogrig A; Zekeridou A; Muñiz-Castrillo S; Velasco R; Guidon AC; Joubert B; Honnorat J
    Lancet Neurol; 2024 Jan; 23(1):81-94. PubMed ID: 38101905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity.
    Farina A; Birzu C; Elsensohn MH; Picca A; Muñiz-Castrillo S; Vogrig A; Villagrán-García M; Ciano-Petersen NL; Massacesi L; Hervier B; Guégan S; Kramkimel N; Vano Y; Salem JE; Allenbach Y; Maisonobe T; Assaad S; Maureille A; Devic P; Weiss N; Pegat A; Maucort-Boulch D; Ricard D; Honnorat J; Psimaras D; Joubert B
    Brain Commun; 2023; 5(3):fcad169. PubMed ID: 37389303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors.
    Duong SL; Prüss H
    Neurotherapeutics; 2022 Apr; 19(3):848-863. PubMed ID: 35043373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors induced side effects of the peripheral nervous system.
    Hundsberger T; Schreiner B; Roth P
    Curr Opin Neurol; 2023 Oct; 36(5):427-431. PubMed ID: 37639489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central nervous system complications associated with immune checkpoint inhibitors.
    Vogrig A; Muñiz-Castrillo S; Joubert B; Picard G; Rogemond V; Marchal C; Chiappa AM; Chanson E; Skowron F; Leblanc A; Ducray F; Honnorat J
    J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):772-778. PubMed ID: 32312871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes.
    Sechi E; Markovic SN; McKeon A; Dubey D; Liewluck T; Lennon VA; Lopez-Chiriboga AS; Klein CJ; Mauermann M; Pittock SJ; Flanagan EP; Zekeridou A
    Neurology; 2020 Oct; 95(17):e2442-e2452. PubMed ID: 32796130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurological autoimmunity in patients with non-pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles.
    Mangioris G; Halfdanarson TR; Lennon VA; Chang BK; Dubey D; Dyck PJB; Flanagan EP; McKeon A; Mills JR; Pittock SJ; Zekeridou A
    Eur J Neurol; 2024 Jun; 31(6):e16273. PubMed ID: 38466015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review.
    Zammit F; Seront E
    Pharmaceuticals (Basel); 2024 Apr; 17(4):. PubMed ID: 38675461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors.
    Graus F; Dalmau J
    Nat Rev Clin Oncol; 2019 Sep; 16(9):535-548. PubMed ID: 30867573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.
    Diamanti L; Picca A; Bini P; Gastaldi M; Alfonsi E; Pichiecchio A; Rota E; Rudà R; Bruno F; Villani V; Galiè E; Vogrig A; Valente M; Zoccarato M; Poretto V; Giometto B; Cimminiello C; Del Vecchio M; Marchioni E
    Neurol Sci; 2022 Mar; 43(3):2031-2041. PubMed ID: 34424427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma.
    Möhn N; Sühs KW; Gingele S; Angela Y; Stangel M; Gutzmer R; Satzger I; Skripuletz T
    Melanoma Res; 2019 Aug; 29(4):435-440. PubMed ID: 30855529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook.
    Möhn N; Beutel G; Gutzmer R; Ivanyi P; Satzger I; Skripuletz T
    J Clin Med; 2019 Oct; 8(11):. PubMed ID: 31653079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.